Phase I/II Study Design of Birinapant in Combination With Keytruda® to be Presented on June 4 at the ASCO Annual Meeting

Phase I/II Study Design of Birinapant in Combination With Keytruda® to be Presented on June 4 at the ASCO Annual Meeting

STOCKHOLM, May 31, 2018 /PRNewswire/ — Medivir AB (Nasdaq Stockholm: MVIR) today informs that the design of the ongoing phase I/II study of birinapant in combination with Keytruda® (pembrolizumab) in advanced cancer patients will be presented during the 2018 American Society for Clinical

Additional remetinostat phase II data will be presented at the International Investigative Dermatology meeting on May 18 and 19

STOCKHOLM, May 18, 2018 /PRNewswire/ — Medivir AB (Nasdaq Stockholm: MVIR) today informs that additional data from the phase II study of remetinostat in patients with early stage cutaneous T-cell lymphoma (CTCL) will be presented during the International Investigative Dermatology (IID) meeting, which will